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Abstract 
School-aged children (SAC) have a considerable burden of intestinal schistosomiasis in Madagascar yet its burden 
in pre-school aged children (PSAC) is currently overlooked. To assess the at-risk status of PSAC, we undertook a pilot 
epidemiological survey in June 2019 examining children (n = 89), aged 2–4-years of balanced gender, in six remote 
villages in Marolambo District, Madagascar. Diagnosis included use of urine-circulating cathodic antigen (CCA) dip-
sticks and coproscopy of stool with duplicate Kato-Katz (K-K) thick smears. Prevalence of intestinal schistosomiasis by 
urine-CCA was 67.4% (95% confidence interval [CI]: 56.5–77.2%) and 35.0% (95% CI: 24.7–46.5%) by K-K. The relation-
ship between faecal eggs per gram (epg) and urine-CCA G-scores (G1 to G10) was assessed by linear regression mod-
elling, finding for every increment in G-score, epg increased by 20.4 (6.50–34.4, P = 0.006). Observed proportions of 
faecal epg intensities were light (78.6%), moderate (17.9%) and heavy (3.6%). Soil-transmitted helminthiasis was noted, 
prevalence of ascariasis was 18.8% and trichuriasis was 33.8% (hookworm was not reported). Co-infection of intestinal 
schistosomiasis and soil-transmitted helminthiasis occurred in 36.3% of PSAC. These results provide solid evidence 
highlighting the overlooked burden of intestinal schistosomiasis in PSAC, and they also offer technical  guidance for 
better surveillance data for the Madagascan national control programme.
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Background
Despite substantial control efforts, schistosomiasis 
remains to be a significant global public health problem, 
particularly in sub-Saharan Africa and Madagascar [1]. 
In Madagascar, 107/114 districts are endemic for schis-
tosomiasis, with the national control programme offering 
praziquantel to school-aged children (SAC), aged 5-15,   
only through school-based mass drug administration 
(MDA) [2]. Given the remoteness of some disease 
endemic villages, many logistical challenges exist and per-
petuate high rates of (re)infection. Recent epidemiologi-
cal studies of SAC have documented very high burdens of 
infection and disease [3]. Both Schistosoma haematobium 
and Schistosoma mansoni exist on Madagascar; S. hae-
matobium causes urogenital schistosomiasis and is pre-
sent in northern and western districts; S. mansoni, which 
causes intestinal schistosomiasis, is present in eastern and 
southern districts; there are areas of co-endemicity in four 
regions in north-central and south-western parts of the 
country [2].  Schistosoma mansoni infection typically pre-
sents with bloody diarrhoea, abdominal pain and bloating 
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[4]. With application of portable ultrasonography, Mala-
gasy children as young as six have detectable periportal 
liver fibrosis, inferring that even younger children have 
developed chronic intestinal schistosomiasis [5].
Across mainland Africa, an estimated 50 million Afri-
can pre-school aged children (PSAC) live with schisto-
somiasis [6], but PSAC are not yet formally included 
in national control strategies [7–9]. Feasible treatment 
options for PSAC include praziquantel crushed tablets 
administered on a test-and-treat basis or can be deliv-
ered in the WHO preventive strategy of ‘Integrated 
Management of Childhood Illnesses’ (IMCI) clinics 
[10, 11]. In contrast to Africa, there are no published 
reports of schistosomiasis among PSAC on Madagas-
car meaning their plight is currently overlooked. To 
address this and better inform the national intervention 
strategy, our pilot study builds on prior findings from 
SAC by MADEX research expeditions [3], to assess 
the current prevalence and infection intensity of intes-
tinal schistosomiasis and soil-transmitted helmin-




A cross-sectional survey was conducted between June-
July 2019 in the hard-to-reach Marolambo District, 
eastern Madagascar. The population is estimated to 
be 250 000 people, of whom 95% are farmers. The pri-
mary source of water is the Nosivolo River (Fig. 1). We 
recruited 89 children aged 2–4-years from six villages: 
Marolambo, Ampasimbola, Ambohitelo, Marofatsy, 
Fig. 1 Map of Marolambo District, Madagascar showing the prevalence of Schistosoma mansoni among 2–4 year-old pre-school children in each 
village. Prevalence by both CCA and Kato-Katz are shown in addition to the arithmetic mean epg of positive PSAC in each village. CCA Circulating 
cathodic antigen, PSAC Pre-school-aged children
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Vohidamba, Betampona; the same sites of previous 
MADEX studies on S. mansoni associated morbid-
ity [3, 5]. In each village 14–15 PSAC, aged 2–4-years 
old, were recruited through convenience sampling. Fol-
lowing community engagement announcing research 
intentions, parents with PSAC were asked if they would 
be willing to volunteer their children for the investiga-
tion. Owing to logistical constraints of available diag-
nostic urine-CCA dipsticks, only the first 15 children in 
each village were examined.
Parasitology
Children were provided with individual sterile sample 
pots labelled with their unique identifiable number (IN) 
which they returned the following day containing their 
mid-stream urine samples and stool samples. Urine was 
not assessed for Schistosoma haematobium as this spe-
cies is not endemic in Marolambo District [3]. Urine 
samples were tested for circulating cathodic antigen 
(CCA; Rapid Medical Diagnostics Tests, Pretoria, South 
Africa) and recorded by the G-scores (G1 to G10) sys-
tem (Fig. 3); a G-score of 1 was considered negative, all 
other scores were considered positive and ranked in 
ascending order with increasing visual intensity of the 
test band [12]. Urine CCA is a rapid, point-of-care test 
for S. mansoni, with a sensitivity of 83% and a specific-
ity of between 81 and 90%, and when used in conjunc-
tion with coproscopy gains in specificity [13, 14]. Faecal 
coproscopy was undertaken by inspection of duplicate 
thick Kato-Katz (K-K) smears (Vestergaard-Frandsen, 
Lausanne, Switzerland) for S. mansoni and for soil-
transmitted helminthiasis. According to World Health 
Organization (WHO) guidelines, S. mansoni infection 
was classified by intensity as light (1–99 eggs per gram; 
epg), moderate (100–399 epg), or heavy (≥ 400 epg); 
Ascaris lumbricoides infection intensity was classified 
as light (1–4999 epg), moderate (5000–49 999 epg) and 
heavy (≥ 50 000 epg); and Trichuris trichiura infection 
intensity was classified as light (1–999 epg), moderate 
(1000–9999 epg) and heavy (≥ 10 000 epg) [15]. The 
presence of hookworms was not recorded for it was not 
possible to read all K-K slides within the required one-
hour window from slide preparation. As a diagnostic 
quality control, 10% of K-K slides were cross-checked 
by The Helminthiases Unit of the Institut Pasteur de 
Madagascar (IPM).
All S. mansoni infected children were treated with 
crushed praziquantel at 40 mg/kg under direct supervi-
sion. STH infected children were treated with a single 
dose of albendazole. Parents were requested to report 
back to the survey team should the child experience any 
immediate discomfort.
Statistical analysis
All results were recorded on electronic tablets in the field. 
Statistical analyses were performed on Stata 2017 (Stata 
Statistical Software 15. College Station, TX: StataCorp 
LLC). Chi-squared and Fisher’s exact tests were used to 
assess for association between prevalence by both urine-
CCA and K-K, with age, gender and village.
Results
S. mansoni prevalence and infection intensity
Our PSAC cohort consisted of balanced gender 
(45M:44F). The prevalence of S. mansoni infection was 
58/86 (67.4%; 95% CI: 56.5–77.2%) by CCA and 28/80 
(35.0%; 95% CI: 24.7–46.5%) by Kato-Katz (Table  1). 
There were no statistically significant differences in prev-
alence by age, gender or location, from either urine-CCA 
or by K-K (Table 1). The arithmetic mean infection inten-
sity of positive individuals was 74.6 epg on K-K (95% CI: 
35.7–113.4). Of the 28 K-K positive children, light infec-
tions were observed in 22/28 (78.6%), moderate intensity 
infections in 5/28 (17.9%) and heavy intensity infections 
in 1/28 (3.6%). The youngest age of infection for any par-
asite was 2-years, noting 2-year old children could have 
moderate intensity infections across all sampled villages 
(Fig. 2). CCA G-score results were skewed towards lower 
scores, where 17.4% had a G-score of G2 and 1.2% had a 
G-score of G10 (Fig. 3).
The linear regression model estimated that in our 
PSAC cohort, for every increase in G-score by a value 
of one, the epg increased by 20.4 (6.50–34.4, P = 0.006; 
Fig. 3). Of note, there were 4/27 (14.8%) and 1/27 (3.7%) 
of children with a G-score of G1 (as judged not infected) 
yet found to have light and moderate intensity infections 
by Kato-Katz, respectively (Fig.  3). Similarly, there were 
30/52 (57.7%) children negative by Kato-Katz, who were 
found to have G-scores > 1 by CCA.
By combining the treatment naïve SAC epg results 
from 2015, with our treatment naïve PSAC epg results, 
an updated simple linear regression estimation pre-
dicts that the first age of infection is likely to be between 
4–12 months (see Additional file 1: Figure S1). Although 
the estimates from this model assume that the epg of 
2015 PSAC is the same as 2019 PSAC, for the purpose 
of estimating the first age of infection this is likely to be 
more accurate than incorporating epg data from SAC 
who have received PZQ due to the loss of the age-preva-
lence correlation [16].
Soil‑transmitted helminthiasis prevalence and infection 
intensity
The prevalence of STH infection was 34/80 (42.5%); asca-
riasis was identified in 15/50 (18.8%), trichuriasis among 
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27/80 (33.8%), and there was 8/80 (10%) with both infec-
tions. All ascariasis was of light infection intensity, while 
11/15 (73.3%) individuals with trichuriasis had light 
intensity infections with the remainder 4/15 (26.7%) of 
moderate intensity. No heavy intensity infections of STHs 
were identified. Co-infection with S. mansoni and STHs 
existed in 29/80 (36.3%) of participants (by CCA for S. 
mansoni and Kato-Katz for STH) and was 12/80 (15.0%, 
by Kato-Katz for both S. mansoni and STH).
Discussion
This pilot study is the first step in drawing attention to 
the burden of schistosomiasis amongst pre-school-aged 
(PSAC) in Madagascar. Despite a limited sample size of 
15 children per village, we report on alarming levels of 
intestinal schistosomiasis in young children currently 
ignored. Upon consideration of egg-patent infections, 
35.0% (95% CI: 24.7–46.5%) of 2–4-year-olds were found 
to have intestinal schistosomiasis. This is unsurpris-
ing given that previous studies have demonstrated the 
Marolambo District to be hyperendemic for intestinal 
schistosomiasis, with school-aged children (aged 5–14) 
having prevalence of 94% by CCA and 74% by Kato-Katz 
[3].
Given the insensitivity of Kato-Katz methodology 
in the detection of light or early acquired infections 
(where worm pairs might not have reached full fecun-
dity), the higher recorded CCA prevalence of 67.4% (95% 
CI: 56.5–77.2%) is to be expected [17]. The majority of 
infected individuals had light egg-patent intensity infec-
tions (76.8%) and some with moderate (17.9%) and heavy 
intensity infections (3.6%). These prevalence and infec-
tion intensity results approximate to the statistical esti-
mates extrapolated from treatment naïve SAC data from 
2015 from the same six villages; a study found a positive 
correlation between age and both prevalence and infec-
tion intensity, predicting light to moderate infections in 
approximately 50% of 2–4-year-old pre-school children 
[3]. As heavy infections were found from 2-year-olds (in 
Ambohitelo village), this further points towards an ear-
lier age of first exposure to schistosome cercariae, and is 
in keeping with observations from both Kenya and Côte 
d’iVoire where children as young as 5 and 6 months old 
(respectively) have been found to have S. mansoni infec-
tion [18, 19]. This is of importance when considering 
treatment age for future schistosomiasis control policies.
There are a number of limitations to consider when 
interpreting our findings. The convenience sampling may 
have resulted in selection bias. Specifically, those who 
volunteered may have been more engaged with schistoso-
miasis education and prevention activities and therefore 
skewed results towards lower disease burdens. Alterna-
tively, parents with concerns about their child’s health 
may have been more willing to volunteer their children 
for participation in the study, skewing the results towards 
higher prevalence and infection intensity. This pilot study 
Fig. 2 Scatter plot of epg data points of infected PSAC by age, for each village. Note the number of dots does not reflect the total number of 
individuals infected in each village (as detailed in Table 1) as some children had the same epg counts (with overlapping dots). This explains why 
there are more dots for four-year-olds than two- or three-year-olds. PSAC Pre-school-aged children, EPG Eggs per gram
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Fig. 3 CCA G-score results: a number of PSAC with each G-score and b correlation between G-score and epg. A Frequency histogram of CCA 
G-scores shows the number of PSAC with each G-score. A child with a score of G1 was considered not-infected, and scores G2-10 were considered 
to be infected with Schistosoma mansoni. B Scatter plot of epg values against CCA G-score values, with linear regression line shown. The linear 
regression model estimated, that in this cohort, for every increase in G-score by a value of one, the epg increased by 20.4 (6.50–34.4, P = 0.006). CCA 
Circulating cathodic antigen, PSAC Pre-school-aged children
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enrolled a small sample of 80 participants as it was the 
first step in assessing prevalence amongst PSAC. This 
small sample size is reflected by large confidence inter-
vals around both prevalence estimates as well as for the 
association between G score and epg. A larger and more 
robust study design would likely yield more accurate and 
representative associations between epg and G scores in 
this population. Despite these limitations, this study pro-
vides important preliminary data about the prevalence 
of schistosomiasis in PSAC. There is a need for further 
studies into the optimal dosing, frequency and timing 
of paediatric praziquantel treatment as well as the need 
for efforts to develop other interventions that can bring 
broader benefit to these afflicted communities, not for-
getting the  fine-scale spatial heterogeneities of typical 
schistosomiasis here and elsewhere.
To our knowledge, this is the first study to present the 
measurement accuracy of CCA G-score on PSAC. A pro-
portion of G1-scores (18.5%; as judged not infected) were 
reported in children with evidence of egg-patent infec-
tion. Studies among SAC have previously reported the 
CCA test specificity to be between 81 and 90%, where 
CCA tests have yielded negative results in egg-patent 
individuals with evidence of light infections, and less 
commonly with moderate or heavy infections [13, 14]. 
The reason for this remains unclear but may be due to 
physiological differences in urinary excretion of CCA 
between children.
Across sub-Saharan Africa there is increasing recog-
nition of schistosome infection among PSAC [20, 21]. 
Untreated, chronic infection leads to significant and det-
rimental effects on health, including stunting, wasting, 
anaemia, reduced exercise tolerance, impaired cognitive 
development or even death from the consequences of 
periportal liver fibrosis [4, 10]. Calprotectin and faecal 
occult blood tests have shown to be effective biomark-
ers for morbidity in S. mansoni in children as young as 
3-years who have been found to have associated anaemia 
and should be attempted to be used in this setting here 
to better describe the burden of disease in PSAC [22]. 
Nonetheless, evident progression towards liver disease 
is clear since our 2016 study identified 11% of SAC had 
sonographic evidence of liver fibrosis, from 6-years of age 
[5]. Similarly, research in Côte d’Ivoire has demonstrated 
sonographic evidence of bladder lesions in PSAC infected 
with S. haematobium that intensifies without treatment 
[23]. As PSAC in Madagascar are not yet included in 
the national control programme [24], many already suf-
fer chronic disease which will only progress further if left 
untreated before primary school age. To prevent disease 
progression, access and delivery of praziquantel to PSAC 
is needed; waiting to provide treatment until children 
are over 5-years of age is not justifiable in the context of 
already evident chronic disease [11].
The anthelmintic praziquantel is well recognised to be 
both a safe and efficacious treatment among PSAC [6]. 
PSAC dosing is extrapolated from adult dosing regimens 
using 40 mg/kg praziquantel crushed in a syrup drink to 
reduce the bitter taste of praziquantel [25, 26], although 
pharmacokinetic and pharmacodynamic data suggests 
higher doses up to 60 mg/kg may be needed [27], and are 
currently being investigated [28]. Efforts towards devel-
oping a paediatric orally dispersible praziquantel tablet 
for children aged 3-months to 6-years are underway with 
ongoing Phase III clinical trials at the time of writing [29, 
30]. All infected children in our age-group were treated 
after the study with appropriate dose of praziquantel and 
the recommended single dose of albendazole for STH 
treatment in line with current dosing recommendations 
and we observed that there were no reported adverse 
effects.
Although WHO guidance from 2010 recommended 
a case-by-case approach to treatment of PSAC with S. 
mansoni infection, realising the pervasive nature of infec-
tions, preventive chemotherapy approaches through 
IMCI strategy, or MDA with praziquantel to include 
PSAC are reasonable [10]. Inclusion of PSAC in the Mad-
agascar national control programme, for example first 
with expanded surveillance then inclusion in treatment 
campaigns using crushed praziquantel, whilst waiting 
for deployment of the paediatric praziquantel formula; 
this is justified as a much-needed step towards reducing 
its public health burden in both SAC and PSAC by 2025 
[31]. There were 36.3% of children co-infected with schis-
tosomiasis and STH in our study, which suggests that 
mass treatment with both albendazole and PZQ may be 
more practical and beneficial than test-and-treat.
Alternative interventions are also desired such as 
improving access to safe water, sanitation and hygiene 
(WASH) facilities, health education for specific behav-
ioural change as well as focal use of molluscicides [15]. 
In Marolambo, communities rely on the Nosivolo river as 
their main water source, for drinking, washing, cooking 
and transport; safer, alternative water sources are limited 
[3]. PSAC are at increased risk of infection and re-infec-
tion through passive water contact if caregivers regu-
larly come into contact with infested water sources [21]. 
Strategies to combat this will have important impacts 
on transmission in children, particularly those less than 
3-years of age [32]. In this setting, consideration of pre-
ventive chemotherapy for ascariasis and trichuriasis is 
also needed which could synergise future drug delivery 
campaigns to improve health of PSAC more broadly. 
In short, hyper-endemic regions such as this should 
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be amongst the first to benefit from deployment of the 
forthcoming paediatric praziquantel formulation.
Conclusions
This pilot study assesses the prevalence and infection 
intensity of S. mansoni and soil transmitted helminths 
amongst PSAC in a hard-to-reach region of Madagascar. 
It provides an important starting point to develop bet-
ter evidence-based policies for control of schistosomiasis 
in Malagasy PSAC. We describe a significant burden of 
intestinal schistosomiasis which further informs policy-
makers of the pressing need to expand future access to 
praziquantel alongside developing strategies that syner-
gise with other child health programmes.
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